Why this matters for drug discovery The GLP-1 agonist clinical pipeline in 2026 is defined by a single trend: each new mechanism pushes weight loss higher
This article explores the possible negative side effects, regulatory considerations, and medical factors that should be evaluated before starting peptide therapy, especially for individuals seeking long-term health improvements
In the US, oral semaglutide (Wegovy pill) launched in January 2026 and saw record-breaking prescription demand within weeks
Sagoe, D., McVeigh, J., Bjrnebekk, A., Essilfie, M.S., Andreassen, C.S
Summary of Key Findings Navigating the intersection of allergy relief and metabolic health does not have to be complicated
Many PlexusDx patients integrate their compounded tirzepatide therapy with continuous glucose monitoring and activity tracking apps to visualize how lifestyle choices interact with medication response at the 25-unit level